# Esprit Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/esprit-pharma

- Industry: Pharmaceuticals
- Headquarters: East Brunswick, US
- Website: www.espritpharma.com
- Total disclosed funding: $96M
- Latest round: Series B (Aug 2, 2006)
- Investors on record: 6

## About

Esprit Pharma, Inc. is a pharmaceutical company focused on developing innovative treatments to address unmet medical needs, particularly in urology and women's health.Founded in 2004 and headquartered in East Brunswick, US, Esprit Pharma, Inc. specializes in producing pharmaceutical products. The company was acquired by Allergan Inc. in September 2007 for USD 370 mn, marking a significant shift in its operational strategy. The CEO is Robert Condon.Esprit Pharma specializes in delivering innovative pharmaceutical products aimed at addressing unmet medical needs. The company's core offerings include a range of prescription medications designed to treat various conditions, particularly in the fields of urology and women's health. These products are developed to enhance patient outcomes through improved efficacy and safety profiles, targeting both healthcare providers and patients directly. Esprit Pharma’s offerings are tailored for specific end-use cases such as chronic urological conditions and gynecological disorders, facilitating better management of these health issues. The company markets its products primarily in North America and select regions in Europe, catering to a diverse customer base that includes hospitals, clinics, and individual healthcare practitioners.Esprit Pharma generates revenue through a structured model that includes direct sales to healthcare providers and partnerships with pharmaceutical distributors. The company engages in B2B transactions, allowing it to streamline its product distribution channels effectively. Revenue is primarily derived from the sales of its flagship products, which are marketed under proprietary brand names that emphasize their distinct therapeutic benefits. Pricing plans for these products are established based on various factors including market demand and therapeutic value, ensuring competitive positioning within the pharmaceutical industry. The financial structure supports a sustainable revenue stream, which is bolstered by ongoing relationships with healthcare professionals who facilitate product adoption and patient prescriptions.Following its acquisition by Allergan Inc. in September 2007, Esprit Pharma plans to leverage its new resources to enhance treatment options for overactive bladder (OAB) symptoms. The recent funding of USD 370 mn will be utilized to support significant improvements in OAB symptoms, which is part of the company's strategy to address unmet medical needs in urology. Esprit Pharma is exploring opportunities for expanding its market presence in both North America and Europe, targeting new healthcare partnerships and distribution agreements to reach a broader audience.

## Funding rounds

- Series B, Aug 2, 2006, $91M — Apax Partners, Domain Associates, New Enterprise Associates, Oak Investment Partners, Greenspring Associates, Sagard Private Equity Solutions
- Series A, May 31, 2005, $5.1M — Apax Partners, Domain Associates, New Enterprise Associates

## Investors

- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series A, Series B
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Oak Investment Partners (https://capitalatlas.ai/funds/oak-investment-partners) — Series B
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series B
- Sagard Private Equity Solutions (https://capitalatlas.ai/funds/sagard-private-equity-solutions) — Series B